CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

761373Orig2s000
761425Orig2s000

Trade Name:	PYZCHIVA
Generic or Proper Name:	ustekinumab-ttwe
Sponsor:	Samsung Bioepis Co., Ltd.
Approval Date:	April 20, 2025
Indication:	Adult patients with: • moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy • active psoriatic arthritis (PsA) • moderately to severely active Crohn's disease (CD) • moderately to severely active ulcerative colitis Pediatric patients 6 years and older with: • moderate to severe plaque psoriasis, who are candidates for phototherapy orsystemic therapy • active psoriatic arthritis (PsA)

CENTER FOR DRUG EVALUATION AND RESEARCH

761373Orig2s000
761425Orig2s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	**X**
Labeling	**X**
REMS	
Officer/Employee List	**X**
Multidiscipline Review(s) • **Summary Review** • **Office Director** • **Clinical** • **Non-Clinical** • **Statistical** • **Clinical Pharmacology**	**X**
Product Quality Review(s)	**X**
Clinical Microbiology / Virology Review(s)	
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

761373Orig2s000
761425Orig2s000

APPROVAL LETTER

BLA 761373/Original 2
BLA 761425/Original 2

BLA APPROVAL

Samsung Bioepis Co., Ltd.
c/o Samsung Bioepis United States Inc.
Attention: Yelena Vaydman
Senior Manager, Regulatory Affairs
400 Frank W Burr Boulevard #125
Teaneck, NJ 07666

Dear Yelena Vaydman:

Please refer to your biologics license application (BLA) dated and received March 30, 2023, and January 29, 2024, and your amendments, submitted under section 351(k) of the Public Health Service Act for Pyzchiva (ustekinumab-ttwe) injection.

We acknowledge receipt of your amendment dated October 31, 2024, which constituted a request for approval following our June 28, 2024, provisional determination letter.

BLA 761373 initially provided for:

- Pyzchiva (ustekinumab-ttwe) injection 45 mg/0.5 mL single-dose prefilled syringe for subcutaneous use as biosimilar to and interchangeable with Stelara (ustekinumab) injection 45 mg/0.5 mL single-dose prefilled syringe for subcutaneous use, and
- Pyzchiva (ustekinumab-ttwe) injection 90 mg/mL single-dose prefilled syringe for subcutaneous use as biosimilar to and interchangeable with Stelara (ustekinumab) injection 90 mg/mL single-dose prefilled syringe for subcutaneous use.

BLA 761425 initially provided for Pyzchiva (ustekinumab-ttwe) injection 130 mg/26 mL single-dose vial for intravenous use as biosimilar to and interchangeable with Stelara (ustekinumab) injection 130 mg/26 mL single-dose vial for intravenous use.

For administrative purposes, BLAs 761373 and 761425 were split as follows:

- BLA 761373/Original 1 – biosimilarity
- BLA 761373/Original 2 – interchangeability
- BLA 761425/Original 1 – biosimilarity
- BLA 761425/Original 2 – interchangeability

The subjects of this correspondence are BLA 761373/Original 2 and BLA 761425/Original 2. A separate correspondence was issued for BLA 761373/Original 1 and BLA 761425/Original 1 on June 28, 2024.

LICENSING

We have approved BLA 761373/Original 2 and BLA 761425/Original 2 for Pyzchiva (ustekinumab-ttwe) as interchangeable biosimilar products effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Pyzchiva, under your existing Department of Health and Human Services U.S. License No. 2046.

Pyzchiva is indicated for the treatment of:

Adult patients with:

- moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy
- active psoriatic arthritis (PsA)
- moderately to severely active Crohn's disease (CD)
- moderately to severely active ulcerative colitis

Pediatric patients 6 years and older with:

- moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy
- active psoriatic arthritis (PsA).

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture ustekinumab-ttwe drug substance at (b) (4). The final formulated drug product will be manufactured and filled at (b) (4), and labeled and packaged at (b) (4). You may label your product with the proprietary name, Pyzchiva, and market it as 45 mg/0.5 mL injection in a single-dose prefilled syringe and 90 mg/mL injection in a single-dose prefilled syringe for subcutaneous use and in 130 mg/26 mL injection in a single-dose vial for intravenous use.

DATING PERIOD

The dating period for Pyzchiva prefilled syringe shall be 36 months from the date of manufacture when stored at 2°C - 8°C protected from light. The dating period for Pyzchiva (130 mg/26 mL) vial presentation shall be 24 months from the date of manufacture when stored at 2°C - 8°C protected from light. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4)

We have approved the stability protocols in your license application for the purpose of extending the expiration dating period of your drug substance and drug product under 21 CFR 601.12.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Pyzchiva to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Pyzchiva, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.[2]

The SPL will be accessible via publicly available labeling repositories.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

At this time, no pediatric assessment will be required under PREA.

[1] See http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

4651-1 Develop an endotoxin testing method for the 5 mg/mL drug product that mitigates the low endotoxin recovery (LER) effect, submit method qualification results with 3 lots of 5 mg/mL drug product, and provide results of a LER study performed with the updated method using 3 lots of drug product. The USP <151> pyrogen test will be replaced by a suitable in vitro endotoxin method upon approval of the supplement.

The timetable you submitted on January 9, 2024, states that you will conduct this study according to the following schedule:

Final Report Submission: 01/2026

Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to the respective BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to the respective BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled "Postmarketing **Commitment Protocol," "Postmarketing Commitment Final Report**," or "**Postmarketing Commitment Correspondence."**

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.[3]

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.[4] Information and Instructions for completing the form can be found at FDA.gov.[5]

[3] For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
[4] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

If you have any questions, contact Chau Nguyen, Regulatory Project Manager at chau.nguyen@fda.hhs.gov or (240)-402-0022.

Sincerely,

{See appended electronic signature page}

Tatiana Oussova, MD, MPH
Deputy Director of Safety
Division of Dermatology and Dentistry

Office of Immunology and Inflammation
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Medication Guide
  - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TATIANA OUSSOVA
04/30/2025 12:57:50 PM